Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 May 2013 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 15 May 2013 |
| Articles of Association for Genmab A/S | 8 May 2013 |
| Genmab Announces Financial Results for the First Quarter of 2013 | 7 May 2013 |
| Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration | 1 May 2013 |
| Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Bendamustine in Untreated and Relapsed Chronic Lymphocytic Leukemia | 1 May 2013 |